Another report demonstrated that inhibition of SIRT1 reduced aromatase mRNA and protein levels in estrogen receptor negative (ER−) breast cancer cells possibly due to loss of ERRα binding to the aromatase promoter and subsequent inhibition of aromatase transcription (Holloway et al., 2013). This evidence concerns the gene ESR1 and breast carcinoma.